SIOPEL-3 Liver Tumour Studies: hepatoblastoma and hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN87675276

Enrollment

500

Registered

2001-07-01

Start date

1998-06-01

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatoblastoma and hepatocellular carcinoma Cancer Malignant neoplasm of liver

Interventions

Standard risk hepatoblastoma Arm 1: Initial Treatment - 1 course cisplatin. Continuation treatment - 5 courses cisplatin/doxorubicin. Surgery after course 3 (if feasible). Arm 2: Initial treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis is hepatoblastoma 2. Pretext is I, II or III 3. No extrahepatic Involvement 4. Age <16 at diagnosis 5. No prior treatment 6. No primary surgery required 7. Lung CT scan performed 8. Initial serum alpha-feta protein value obtained (greater than or 100 ng/ml)

Exclusion criteria

Exclusion criteria: Pretext 4, extra hepatic disease, lung metastases, tumour rupture.

Design outcomes

Primary

Measure	Time frame
Complete resection	—

Secondary

Measure	Time frame
Toxicity measures, survival and event-free survival	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026